Mitochondrial function
|
1. ATP5O
|
Subunit of ATP synthase
|
ATP synthesis, Hydrogen ion transport
|
Prognostic marker in renal cancer (favorable)
|
2. RPS25
|
Mitochondrial ribosomal protein L22
|
|
Not prognostic
|
3. COA6
|
Cytochrome c oxidase assembly factor 6
|
Mitochondrial respiration
|
Prognostic marker in renal cancer (unfavorable) and urothelial cancer (favorable)
|
Complement pathway
|
4. CLU
|
Clusterin
|
Apoptosis, Complement pathway, Innate immunity
|
Prognostic marker in thyroid cancer (favorable
|
5. C4BPA
|
Complement component 4 binding protein alpha
|
Complement pathway/Innate immunity
|
Prognostic marker in endometrial cancer (favorable) and liver cancer (favorable
|
6. C4A
|
Complement C4A
|
Systemic lupus erythematosus,
|
Not prognostic
|
7. C5
|
Complement C5
|
Complement pathway/Innate Immunity/Inflammatory response
|
Prognostic marker in liver cancer (favorable)
|
8. C3
|
Complement C3
|
Age-related macular degeneration, Hemolytic uremic syndrome,
|
Prognostic marker in renal cancer (unfavorable) and liver cancer (favorable)
|
Structural Protein
|
9. CLTC
|
Clathrin heavy chain
|
Autophagy, Cell cycle/division/mitosis
|
Prognostic marker in urothelial cancer (unfavorable), liver cancer (unfavorable), cervical cancer (unfavorable) and colorectal cancer (favorable)
|
10. FGA
|
Fibrinogen alpha chain
|
Amyloidosis, Cancer-related gene
|
Prognostic marker in renal cancer (unfavorable) and liver cancer (favorable)
|
11. MYH10
|
Myosin heavy chain 10
|
Actin/Calmodulin-binding, Motor protein
|
Prognostic marker in renal cancer (favorable) and urothelial cancer (unfavorable)
|
12. PFN1
|
Profilin 1
|
Actin binding
|
Prognostic marker in renal cancer (unfavorable)
|
13. TAGLN
|
Transgelin
|
Actin binding
|
Prognostic marker in renal cancer (unfavorable)
|
14. FSCN1
|
Faschin actin binding protein
|
Actin binding
|
Prognostic marker in renal cancer (unfavorable), lung cancer (unfavorable) and head and neck cancer (unfavorable)
|
15. CAPZB
|
F-actin-capping protein subunit beta
|
Actin capping, Actin binding
|
Prognostic marker in renal cancer (favorable) and liver cancer (unfavourable)
|
16. CTTNBP2NL
|
CTTNBP2 N-terminal-like protein
|
Actin dynamic
|
Prognostic marker in colorectal cancer (favorable) and renal cancer (favourable)
|
17. A2M
|
Alpha-2-macroglobulin
|
Cancer-related gene
|
Not prognostic
|
18. THBS1
|
Thrombospondin 1
|
Heparin-binding, Cell adhesion
|
Prognostic marker in renal cancer (unfavorable) and stomach cancer (unfavorable)
|
19. VTN
|
Vitronectin
|
Cell adhesion, Cancer-related genes
|
Prognostic marker in renal cancer (unfavorable) and liver cancer (favorable)
|
20. DSC3
|
Desmocollin
|
Cell adhesion
|
Prognostic marker in urothelial cancer (unfavorable)
|
21. POSTN
|
Periostin
|
Cell adhesion
|
Prognostic marker in renal cancer (unfavorable), lung cancer (unfavorable) and stomach cancer (unfavorable)
|
Metabolism
|
22. DLST
|
Dihydrolipoamide
S-succinyltransferase
|
TCA cycle
|
Prognostic marker in renal cancer (favorable)
|
23. ENO2
|
Enolase 2
|
Glycolysis, Cancer-related genes
|
Prognostic marker in renal cancer (unfavorable), liver cancer (unfavorable) and colorectal cancer (unfavorable)
|
24. ENO3
|
Enolase 3
|
Glycolysis
|
Prognostic marker in colorectal cancer (unfavorable)
|
25. PGK2
|
Phosphoglycerate kinase 2
|
Glycolysis
|
Not prognostic
|
26. PKLR
|
Pyruvate kinase L/R
|
Glycolysis
|
Not prognostic
|
27. TKT
|
Transketolase
|
Transketolase
|
Prognostic marker in liver cancer (unfavorable)
|
28. TXN
|
Thioredoxin
|
Antioxidant
|
Prognostic marker in endometrial cancer (favorable)
|
Protein synthesis
|
29. EEF1A2
|
Eukaryotic translation elongation factor 1 alpha 2
|
Protein biosynthesis, GTP binding
|
Prognostic marker in endometrial cancer (unfavorable) and head and neck cancer (unfavorable
|
30. EIF4A2
|
Eukaryotic translation initiation factor 4A2
|
Protein synthesis, RNA binding;
|
Not prognostic
|
31. EEF1A1
|
Eukaryotic translation elongation factor 1 alpha 1
|
Protein biosynthesis, Transcription,
|
Prognostic marker in liver cancer (unfavorable)
|
32. EEF1G
|
Eukaryotic translation elongation factor 1 gamma
|
Protein biosynthesis
|
Not prognostic
|
33. EIF3I
|
Eukaryotic translation initiation factor 3 subunit I
|
Protein biosynthesis
|
Prognostic marker in renal cancer (unfavorable), endometrial cancer (favorable) and liver cancer (unfavorable)
|
34. FAU
|
ubiquitin like and ribosomal protein S30 fusion
|
Ribosomal protein
|
Not prognostic
|
35. RPL7
|
Ribosomal protein L7
|
Ribosomal protein
|
Not prognostic
|
36. RPL7A
|
Ribosomal protein L7a
|
Ribosomal protein
|
Prognostic marker in ovarian cancer (unfavorable) and liver cancer (unfavorable)
|
37. RPL10
|
Ribosomal protein L10
|
Ribosomal protein
|
Prognostic marker in renal cancer (unfavorable)
|
38. RPL10L
|
Ribosomal protein L10 like
|
Ribosomal protein
|
Not prognostic
|
39. RPL13
|
Ribosomal protein L13
|
Ribosomal protein
|
Prognostic marker in endometrial cancer (favorable) and renal cancer (unfavorable)
|
40. RPL13A
|
Ribosomal protein L13a
|
Ribosomal protein
|
Prognostic marker in renal cancer (unfavorable) and liver cancer (unfavorable)
|
41. RPL18
|
Ribosomal protein L18
|
Ribosomal protein
|
Prognostic marker in renal cancer (unfavorable)
|
42. RPL22
|
Ribosomal protein L22
|
Ribosomal protein
|
Not prognostic
|
43. RPL24
|
Ribosomal protein L24
|
Ribosomal protein
|
Prognostic marker in renal cancer (unfavorable) and thyroid cancer (favorable)
|
44. RPL27
|
Ribosomal protein L27
|
Ribosomal protein
|
Prognostic marker in renal cancer (unfavorable)
|
45. RPL29
|
Ribosomal protein L29
|
Ribosomal protein
|
Not prognostic
|
46. RPLP2
|
Ribosomal protein lateral stalk subunit P2
|
Ribosomal protein
|
Prognostic marker in renal cancer (unfavorable) and liver cancer (unfavorable)
|
47. RPS3A
|
Ribosomal protein S3A
|
Ribosomal protein
|
Prognostic marker in liver cancer (unfavorable)
|
48. RPS16
|
Ribosomal protein S16
|
Ribosomal protein
|
Not prognostic
|
49. RPS11
|
Ribosomal protein S11
|
Ribosomal Protein
|
Prognostic marker in renal cancer (unfavorable)
|
Nucleic acid binding
|
50. HNRNPA2B1
|
Heterogeneous nuclear ribonucleoprotein A2/B1
|
Ribonucleoprotein, RNA-binding
|
Prognostic marker in liver cancer (unfavorable), renal cancer (unfavorable) and prostate cancer (unfavorable)
|
51. HNRNPA1L2
|
Heterogeneous nuclear ribonucleoprotein A1-like 2
|
Packaging of pre-mRNA/ transport of mRNA/splice site selection.
|
Prognostic marker in breast cancer (favorable) and pancreatic cancer (favorable)
|
52. HNRNPA1
|
Heterogeneous nuclear ribonucleoprotein A1
|
mRNA processing/splicing/ transport
|
Most cancer tissues show moderate to strong nuclear staining. Not prognostic.
|
53. NCL
|
Nucleolin
|
DNA/RNA-binding
|
Prognostic marker in liver cancer (unfavorable) and endometrial cancer (unfavorable)
|
54. HNRNPA3
|
Heterogeneous nuclear ribonucleoprotein A3
|
Trafficking of RNA/ Pre-mRNA splicing
|
Prognostic marker in renal cancer (unfavorable), liver cancer (unfavorable) and cervical cancer (favorable)
|
Chaperone, Heat shock Protein
|
55. HSPA1L
|
Heat shock protein family A (Hsp70) member 1 like
|
Molecular chaperone, cancer related gene
|
Prognostic marker in ovarian cancer (favorable) and renal cancer (favorable)
|
56. HSPA6
|
Heat shock protein family A (Hsp70) member 6
|
Molecular chaperone, stress response
|
Prognostic marker in renal cancer (unfavorable) and liver cancer (unfavorable)
|
57. HSP90AA1
|
Heat shock protein 90 alpha family class A member 1
|
Molecular chaperone, Cancer-related genes
|
Prognostic marker in renal cancer (favorable), liver cancer (unfavorable) and breast cancer (unfavorable)
|
58. HSPA2
|
Heat shock protein family A (Hsp70) member 2
|
Chaperone, cancer related gene
|
Prognostic marker in breast cancer (favorable) and lung cancer (unfavorable)
|
59. CCT3
|
Chaperonin containing TCP1subunit 3
|
Chaperone
|
Prognostic marker in liver cancer (unfavorable) and renal cancer (unfavorable)
|
60. CCT7
|
Chaperonin containing TCP1subunit 7
|
Chaperone
|
Prognostic marker in liver cancer (unfavorable) and endometrial cancer (unfavorable)
|
Immunity
|
61. HLA-A
|
Major histocompatibility complex, class I, A
|
Adaptive & Innate immunity
|
Prognostic marker in ovarian cancer (favorable) and endometrial cancer (favorable)
|
62. HLA-B
|
Major histocompatibility complex, class I, B
|
Adaptive & Innate immunity
|
Prognostic marker in melanoma (favorable)
|
63. HLA-C
|
Major histocompatibility complex, class IC
|
Adaptive & Innate immunity
|
Not prognostic
|
Transport
|
64. RAB1A
|
RAB1A, member RAS oncogene family
|
Autophagy, ER-Golgi transport, Protein transport
|
Prognostic marker in head and neck cancer (unfavorable)
|
65. RAB5A
|
Member, RAS oncogene family
|
Endocytosis, Phagocytosis, Protein transport
|
Not prognostic
|
66. RAB5B
|
Member RAS oncogene family
|
Protein transport
|
Prognostic marker in breast cancer (unfavorable)
|
67. RAB5C
|
Member RAS oncogene family
|
Protein transport
|
Prognostic marker in head and neck cancer (unfavorable)
|
68. SLC25A4
|
Solute carrier family 25 member 4
|
Host-virus interaction, Transport
|
Prognostic marker in renal cancer (favorable) and pancreatic cancer (favorable)
|
69. SLC25A6
|
Solute carrier family 25 member 6
|
Apoptosis, Transport
|
Not prognostic
|
70. NASP
|
Nuclear autoantigenic sperm protein
|
Cell cycle, DNA replication and protein transport
|
Prognostic marker in renal cancer (unfavorable), liver cancer (unfavorable) and melanoma cancer (unfavorable)
|
Nucleotide binding
|
71. ARF4
|
ADP ribosylation factor 4
|
GTP-binding, Nucleotide-binding
|
Prognostic marker in liver cancer (unfavorable) and thyroid cancer (unfavorable)
|
72. ARF5
|
ADP ribosylation factor 5
|
GTP-binding, Nucleotide-binding,
|
Not prognostic
|
73. TUBB1
|
Tubulin beta 1 class VI,
|
GTP-binding, Nucleotide-binding
|
Gene product is not prognostic
|
74. TUBB2B
|
Tubulin beta 2B class IIb;
|
GTP-binding, Nucleotide-binding;
|
Prognostic marker in endometrial cancer (unfavorable)
|
75. TUBB4A
|
Tubulin beta 4A class Iva;
|
GTP-binding, Nucleotide-binding;
|
Prognostic marker in endometrial cancer (unfavorable)
|
76. TUBB6
|
Tubulin beta 6 class V;
|
GTP-binding, Nucleotide-binding
|
Prognostic marker in renal cancer (unfavorable) and urothelial cancer (unfavorable
|
77. TUBB3
|
Tubulin beta 3 class III
|
GTP-binding, Nucleotide-binding;
|
Not prognostic
|
78. TUBB
|
Tubulin beta class I
|
GTP-binding, Nucleotide-binding;
|
Prognostic marker in renal cancer (unfavorable) and liver cancer (unfavorable)
|
79. TUBB4B
|
Tubulin beta 4B class IVb
|
GTP-binding, Nucleotide-binding;
|
Prognostic marker in thyroid cancer (favorable), endometrial cancer (favorable) and liver cancer (unfavorable)
|
80. TUBB2A
|
Tubulin beta 2A class IIa
|
GTP-binding, Nucleotide-binding
|
Prognostic marker in urothelial cancer (unfavorable) and renal cancer (favorable)
|
81. TUBB8
|
Tubulin beta 8 class VIII;
|
GTP-binding, Nucleotide-binding;
|
Not prognostic
|
Signalling
|
82. YWHAB
|
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta
|
Signalling, cancer related
|
Prognostic marker in liver cancer (unfavorable), renal cancer (favorable), endometrial cancer (unfavorable), lung cancer (unfavorable), head and neck cancer (unfavorable) and breast cancer (unfavorable)
|
83. YWHAQ
|
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein theta
|
Signalling
|
Prognostic marker in liver cancer (unfavorable) and endometrial cancer (unfavorable)
|
84. YWHAZ
|
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta
|
Signalling
|
Prognostic marker in renal cancer (unfavorable), pancreatic cancer (unfavorable), liver cancer (unfavorable), endometrial cancer (unfavorable) and lung cancer (unfavorable)
|
85. STRN
|
Striatin
|
Signalling
|
Prognostic marker in renal cancer (favorable)
|
86. PHB
|
Prohibitin
|
Signalling, DNA synthesis
|
Prognostic marker in head and neck cancer (unfavorable), renal cancer (favorable) and liver cancer (unfavorable)
|
87. SLMAP
|
Sarcolemma associated protein
|
Signalling
|
Prognostic marker in renal cancer (favorable) and lung cancer (unfavorable)
|
88. CALM3
|
Calmodulin 3
|
Signalling
|
Prognostic marker in lung cancer (unfavorable) and thyroid cancer (favorable)
|
89. RACK1
|
Receptor for activation C kinase 1
|
Cell cycle, Apoptosis, Translational regulation
|
Prognostic marker in liver cancer (unfavorable)
|
Miscellaneous
|
90. SERPINC1
|
Serpin family C member 1
|
Thrombophilia
|
Prognostic marker in liver cancer (favorable)
|
91. SUMO4
|
Small ubiquitin-like modifier 4
|
Ubl conjugation pathway
|
Not prognostic
|
92. SUMO2
|
Small ubiquitin-like modifier 2
|
Ubl conjugation pathway
|
Prognostic marker in renal cancer (unfavorable), endometrial cancer (unfavorable) and liver cancer (unfavorable)
|
93. TLN1
|
Talin 1
|
Host-virus interaction
|
Prognostic marker in colorectal cancer (unfavorable) and renal cancer (favorable)
|
94. HPX
|
Hemopexin
|
Host-virus interaction
|
Prognostic marker in liver cancer (favourable)
|
95. PPIA
|
Peptidylprolyl isomerase A
|
Host-virus interaction
|
Prognostic marker in liver cancer (unfavorable)
|
96. CDC42
|
Cell division cycle 42,
|
Mental retardation
|
Prognostic marker in liver cancer (unfavorable)
|
97. CALR
|
Calreticulin
|
Calcium, Zinc-binding, Cancer related
|
Prognostic marker in renal cancer (unfavorable) and ovarian cancer (favorable)
|
98. CTSD
|
Cathepsin D
|
Proteolysis
|
Prognostic marker in renal cancer (unfavourable) and colorectal cancer (unfavorable)
|
99. CP
|
Ceruloplasmin
|
Ion transport
|
Prognostic marker in renal cancer (unfavourable)
|
100. TMEM109
|
Transmembrane protein 109
|
Ion transport
|
Prognostic marker in urothelial cancer (unfavourable)
|
101. SPYL1
|
Shynaptophysin like 1
|
Transport
|
Prognostic marker in renal cancer (favourable)
|
102. SIX5
|
SIX homeobox 5
|
Transcription
|
Not prognostic
|
103. PCYOX1
|
Prenylcysteine oxidase 1
|
Ion transport, Protein catabolism
|
Prognostic marker in renal cancer (favourable)
|
104. POTEE
|
POTE ankyrin domain family member E
|
Extracellular protein
|
Not prognostic
|